SBFM — Sunshine Biopharma Balance Sheet
0.000.00%
- $5.49m
- -$4.18m
- $34.87m
Annual balance sheet for Sunshine Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.99 | 2.05 | 21.8 | 16.3 | 9.69 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.002 | 0.008 | 1.91 | 2.55 | 3.87 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.03 | 2.2 | 27.3 | 24.9 | 26 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.02 | 0.007 | 1.15 | 1.01 | 1.48 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 1.05 | 2.2 | 29.2 | 27.3 | 30.6 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.05 | 0.091 | 6.93 | 5.55 | 6.31 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 2 | 1.99 | 7.62 | 6.14 | 7.06 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.955 | 0.212 | 21.6 | 21.2 | 23.5 |
Total Liabilities & Shareholders' Equity | 1.05 | 2.2 | 29.2 | 27.3 | 30.6 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |